AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Use of computational software in drug research is growing, and some big tech companies are angling for a piece of this market. Cadence Design Systems is entering the life sciences sector through the $500 million acquisition of OpenEye Scientific, a company that provides computational drug design software to the pharmaceutical industry.
How Apella leverages technology to increase OR efficiency.
Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. In other M&A news, cancer biotech F-star Therapeutics is being acquired in a $161 million deal.
AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based on research from Belgian pharmaceutical company UCB.
According to a report by professional services firm EY, companies that want to grow, focus and innovate will drive dealmaking in 2020, though activity may not reach the record level set in 2019 — $357 billion as of the end of November.
Abbott Labs filed a complaint in a Delaware court citing that Alere has numerous problems and the court should allow it to bow out of its proposed plan to buy Alere for $5.8 billion.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
International M&A in the life sciences is picking up steam, according to a new Mergermarket report - with new focus on the fields of early stage drug discovery and precision medicine.